Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 3/20 | 0.56 |
| ▸ | CTSK | P43235 | 3/20 | 0.56 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 3/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA7 | P43166 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3725798 | 1.00 | CTSS (0.56) | CTSSCTSKPSENENCA2CA1 | |
| SCHEMBL7597660 | 0.91 | CTSS (0.53) | CTSSCTSKPSENENCA2CA1 | |
| SCHEMBL3728289 | 0.90 | CTSK (0.51) | CTSSCTSKPSENENCA2CA1 | |
| SCHEMBL3737231 | 0.87 | CTSK (0.58) | CTSSCTSKPSENENCA2CA1 | |
| SCHEMBL3737229 | 0.87 | CTSK (0.58) | CTSSCTSKPSENENCA2CA1 | |
| SCHEMBL28233243 | 0.84 | CTSK (0.44) | CTSSCTSKPSENENCA2CA1 | |
| SCHEMBL1951088 | 0.84 | CTSS (0.67) | CTSSCTSKPSENENCA2CA1 | |
| SCHEMBL12189206 | 0.84 | CTSS (0.67) | CTSSCTSKPSENENCA2CA1 | |
| SCHEMBL905289 | 0.84 | CTSS (0.67) | CTSSCTSKPSENENCA2CA1 | |
| SCHEMBL3825684 | 0.84 | CTSS (0.67) | CTSSCTSKPSENENCA2CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7825238-B2 | Antiviral methods employing double esters of 2′, 3′-dideoxy-3′-fluoroguanosine | MEDIVIR AB (SE) | 2010-11-02 | — | — | US | disclosed |
| US-7071173-B2 | Antiviral methods employing double esters of 2′, 3′-dideoxy-3′-fluoroguanosine | MEDIVIR AB (SE) | 2006-07-04 | — | — | US | disclosed |
| US-20060122383-A1 | Antiviral methods employing double esters of 2', 3'-dideoxy-3'-fluoroguanosine | MEDIVIR AB (SE) | 2006-06-08 | — | — | US | disclosed |
| US-20060058259-A1 | ANTIVIRAL METHODS EMPLOYING DOUBLE ESTERS OF 2', 3'-DIDEOXY-3'-FLUOROGUANOSINE | MEDIVIR AB (SE) | 2006-03-16 | — | — | US | disclosed |
| US-6974802-B2 | Treatment of viral infections using prodrugs of 2′,3-dideoxy,3′-fluoroguanosine | MEDIVIR AB (SE) | 2005-12-13 | — | — | US | disclosed |
| US-20030186924-A1 | Prodrugs | MEDIVIR AB | 2003-10-02 | — | — | US | disclosed |
| US-6458772-B1 | Prodrugs | MEDIVIR AB (SE) | 2002-10-01 | — | — | US | disclosed |
| EP-1123935-A2 | 3'-Fluorinated guanosine derivatives for the treatment or prophylaxis of HBV or retroviral infections | MEDIVIR AB (SE) | 2001-08-16 | — | — | EP | disclosed |
| EP-0988304-B1 | NUCLEOSIDES ANALOGUES, SUCH AS ANTIVIRALS INCLUDING INHIBITORS OF RETROVIRAL REVERSE TRANSCRIPTASE AND THE DNA POLYMERASE OF HEPATITIS B VIRUS (HBV) | MEDIVIR AB (SE) | 2001-05-02 | — | — | EP | disclosed |
| EP-1054891-A1 | PRODRUGS | MEDIVIR AB (SE) | 2000-11-29 | — | — | EP | disclosed |
| EP-0988304-A1 | NUCLEOSIDES ANALOGUES, SUCH AS ANTIVIRALS INCLUDING INHIBITORS OF RETROVIRAL REVERSE TRANSCRIPTASE AND THE DNA POLYMERASE OF HEPATITIS B VIRUS (HBV) | MEDIVIR AB (SE) | 2000-03-29 | — | — | EP | disclosed |
| WO-1999041275-A1 | PRODRUGS | MEDIVIR AB (SE) | 1999-08-19 | — | — | WO | disclosed |
| WO-1999009031-A1 | NUCLEOSIDES ANALOGUES, SUCH AS ANTIVIRALS INCLUDING INHIBITORS OF RETROVIRAL REVERSE TRANSCRIPTASE AND THE DNA POLYMERASE OF HEPATITIS B VIRUS (HBV) | MEDIVIR AB (SE) | 1999-02-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060058259-A1 | ANTIVIRAL METHODS EMPLOYING DOUBLE ESTERS OF 2', 3'-DIDEOXY-3'-FLUOROGUANOSINE | UNG, HAVCR2, EIF2AK2 | CTSS 1386/4885CTSK 1583/4885PSENEN 3715/4885 |
| US-20030186924-A1 | Prodrugs | HAVCR2, CYP7A1, IGSF11 | CTSS 1913/4885CTSK 2547/4885PSENEN 902/4885 |
| US-20060122383-A1 | Antiviral methods employing double esters of 2', 3'-dideoxy-3'-fluoroguanosine | UNG, HAVCR2, EIF2AK2 | CTSS 1386/4885CTSK 1583/4885PSENEN 3715/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.